Endocrine and Metabolic Science最新文献

{"title":"Exploring the role of adipose tissue-derived hormones asprosin and leptin in the onset of depressive symptoms in newly diagnosed prediabetic individuals","authors":"Faize Elif Bahadir ,&nbsp;Ozlem Unay Demirel ,&nbsp;Melike Yavuz ,&nbsp;Ozum Firat ,&nbsp;Irem Yogurtcu ,&nbsp;Yavuz Govdeli ,&nbsp;Yavuz Furuncuoglu","doi":"10.1016/j.endmts.2025.100231","DOIUrl":"10.1016/j.endmts.2025.100231","url":null,"abstract":"<div><h3>Background</h3><div>Type 2 diabetes and depression are common chronic conditions that often co-occur, likely driven by complex mechanisms that are not yet fully understood. Chronic low-grade inflammation may serve as a shared underlying factor in both conditions. This study aimed to determine whether adipose tissue-derived hormones asprosin and leptin, particularly asprosin, which is associated with inflammatory cytokines in glucose metabolism dysregulation and has not been studied in this context—might influence the onset of depressive symptoms.</div></div><div><h3>Methods</h3><div>112 participants were recruited from drug-naïve individuals. Blood samples were collected, anthropometric data recorded, the Beck Depression/Anxiety Inventories administered. Adapted questions assessed physical and social activity, as well as sleep habits, to account for environmental factors. After applying the exclusion criteria, participants were divided into prediabetic (n = 32) and normoglycemic groups (n = 30).</div></div><div><h3>Results</h3><div>In the prediabetic group CRP was elevated (p &lt; 0.001), with a positive correlation between asprosin and leptin (p &lt; 0.001). Asprosin was positively correlated with TNF-α (p = 0.004), IL-6 (p = 0.002), and ESR (p &lt; 0.001), and leptin with TNF-α (p = 0.008) and ESR (p = 0.018) but not with depressive symptoms or anxiety. Depressive symptoms were higher in prediabetic individuals with poor sleep quality.</div></div><div><h3>Conclusion</h3><div>In groups with similar social and physical activity levels, poor sleep quality was associated with increased depressive symptoms. While asprosin and leptin correlated with higher inflammatory cytokines, they showed no significant association with depression, possibly due to the small sample size and early-stage evaluation. Larger studies are needed to confirm any potential link between these hormones and depression.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100231"},"PeriodicalIF":0.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effectiveness of Rosuvastatin in controlling LDL-C and non-HDL-C levels in hypertensive patients with or without diabetes mellitus","authors":"To Anh Tan Le ,&nbsp;An Viet Tran ,&nbsp;Son Kim Tran ,&nbsp;Chau Minh Tran ,&nbsp;Dang Khoa Dang Tran ,&nbsp;Duy Huu Duong ,&nbsp;Toan Hoang Ngo","doi":"10.1016/j.endmts.2025.100230","DOIUrl":"10.1016/j.endmts.2025.100230","url":null,"abstract":"<div><h3>Background</h3><div>LDL-C and non-HDL-C are contributing risk factors in the development of cardiovascular disease and stroke, exacerbating hazardous cardiovascular events. Rosuvastatin is a widely used statin globally, and a thorough assessment of its efficacy in hypertensive patients with or without diabetes mellitus is essential.</div></div><div><h3>Objectives</h3><div>This study aims to compare the efficacy of Rosuvastatin 20 mg in controlling LDL-C and non-HDL-C in hypertensive patients with and without diabetes.</div></div><div><h3>Methods</h3><div>A cross-sectional descriptive study on 126 primary hypertensive patients (72 hypertensive patients with diabetes and 54 hypertensive patients without diabetes) treated with Rosuvastatin based on cardiovascular risk stratification according to SCORE to assess the efficiency of achieving treatment targets.</div></div><div><h3>Results</h3><div>In hypertensive patients without diabetes (n = 54; 42.9 %), the average age was higher (63.52 ± 8.68 years) and predominantly female (70.4 %) compared to those with diabetes (n = 72; 57.1 %). After 12 weeks of Rosuvastatin 20 mg treatment, non-diabetic patients exhibited more significant improvements in lipid profiles, notably marked decreases in LDL-C and non-HDL-C levels (p &lt; 0.001). The treatment targets for LDL-C were achieved by 27.8 % of diabetic patients and 20.4 % of non-diabetic patients, while the targets for non-HDL-C were achieved by 40.3 % of diabetic patients and 41.5 % of non-diabetic patients. History of stroke and coronary artery disease was significantly associated with increased LDL-C and non-HDL-C in both pre-and post-treatment in both groups.</div></div><div><h3>Conclusion</h3><div>The utilization of Rosuvastatin 20 mg has shown efficacy in ameliorating elevated LDL-C and non-HDL-C levels in primary hypertensive patients. Specifically, in the hypertensive group without diabetes, Rosuvastatin 20 mg aids in better control of LDL-C and non-HDL-C compared to the hypertensive group with diabetes.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100230"},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The last update on polycystic ovary syndrome(PCOS), diagnosis criteria, and novel treatment","authors":"Arghavan Ghafari ,&nbsp;Malihe Maftoohi ,&nbsp;Mohammadamin Eslami Samarin ,&nbsp;Sepideh Barani ,&nbsp;Majid Banimohammad ,&nbsp;Reza Samie","doi":"10.1016/j.endmts.2025.100228","DOIUrl":"10.1016/j.endmts.2025.100228","url":null,"abstract":"<div><div>Polycystic Ovary Syndrome (PCOS) is a prevalent reproductive disease influencing 4–20 % of women, often resulting in delayed diagnosis and correlated metabolic issues such as obesity and insulin resistance, impacting their quality of life. Diagnosis is guided according to the Rotterdam criteria, oligo-anovulation, polycystic ovary morphology, and incorporating hyperandrogenism, with Anti-Müllerian hormone as an indicator for ovary morphology. PCOS management necessitates a multifaceted approach, including lifestyle modifications, weight loss strategies, dietary adjustments, and pharmacological interventions. Lifestyle interventions, comprising exercise regimens, dietary modifications, and behavioral strategies, exhibit the potential to enhance metabolic health among PCOS patients. While no singular diet or exercise regimen emerges as superior, the Mediterranean and ketogenic diets have demonstrated favorable effects. Pharmacological interventions, such as combined oral contraceptives, metformin, and clomiphene citrate, assume pivotal roles in regulating menstrual cycles and mitigating hyperandrogenism symptoms. Personalized approaches, tailored to individual responses, are imperative for optimizing outcomes in the management of PCOS.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100228"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of metabolic syndrome in the occurrence of hearing disorders in the Democratic Republic of Congo","authors":"Jérôme Gedikondele Sokolo ,&nbsp;Aliocha Natuhoyila Nkodila ,&nbsp;Gabriel Mabwaka Lema ,&nbsp;Richard Nzanza Matanda ,&nbsp;Pius Zakayi Kabututu ,&nbsp;Benjamin Longo-Mbenza","doi":"10.1016/j.endmts.2025.100227","DOIUrl":"10.1016/j.endmts.2025.100227","url":null,"abstract":"<div><h3>Background</h3><div>The assessment of hearing function in human life is important, because good hearing is important for social participation and inclusion in employment and education. The objective of this study is to evaluate the influence of metabolic syndrome in the occurrence of hearing disorders in patients followed in hospitals in Kinshasa.</div></div><div><h3>Methods</h3><div>This was an analytical cross-sectional study that included 400 patients consulted in 7 hospitals in the city province of Kinshasa during the period from January 2005 to September 2020. Sociodemographic, clinical, and biological data were analyzed. Multivariate logistic regression analysis and discriminant analysis were used as a basis to document the factors associated with hearing disorders in the study population; and the statistical significance threshold was <em>p</em> &lt; 5 %.</div></div><div><h3>Results</h3><div>The frequency of hearing loss was 40.1 % in patients with metabolic syndrome. Risk factors identified for the occurrence of hearing loss in patients with metabolic syndrome were age ≥ 60 years (aOR: 2.73 95 % CI: 1.37–5.42), waist circumference &gt; 85 cm (Female) or &gt; 94 cm (Male) (aOR: 2.65 95 % CI: 1.37–3.72); blood glucose ≥126 mg/dL (aOR: 2.86 95 % CI: 1.32–6.17), BMI ≥25 kg/m2 (aOR: 2.73 95 % CI: 1.89–3.32) and in patients with insulinemia &gt;10 IU/L (aOR: 3.37 95 % CI: 1.47–7.76).</div></div><div><h3>Conclusion</h3><div>The frequency of hearing loss is high in the population studied. The components of the metabolic syndrome were identified as independent determinants of hearing loss.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100227"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distribution of norepinephrine and acetylcholine receptors in ovarian structures across reproductive and senescent phases in rats","authors":"Juan Bravo-Benítez ,&nbsp;María E. Rivera-Castro ,&nbsp;Cesar F. Pastelín ,&nbsp;Ithayetsi Sarmiento ,&nbsp;Amayrani Hernández ,&nbsp;Alfonso Díaz ,&nbsp;Carolina Morán","doi":"10.1016/j.endmts.2025.100225","DOIUrl":"10.1016/j.endmts.2025.100225","url":null,"abstract":"<div><div>The autonomic nerves in the mammalian ovary are responsible for transmitting the neurotransmitters norepinephrine and acetylcholine, among others. Interestingly, some ovarian innervation becomes more active toward the end of life. The objective of this study was to examine the presence of adrenergic (A1R) and muscarinic (M1R) receptors in adult and senescent female rats. Female rats were divided into three groups according to age: young adults aged 3 to 5 months (3M), middle-aged rats aged 12 months (12M), and senescent rats aged 15 months (15M). Primary antibodies targeting the α1-adrenergic receptor, μ1-muscarinic receptor, 17β-estradiol receptor (ER), and α1-progesterone receptor (PR) were used. Immunoreactivity analysis covered the ovarian stroma and cells around functional structures such as the corpus luteum, ovarian cysts, and follicles. Both receptor antibodies stained these structures, but the noradrenergic binding was three times more abundant than cholinergic binding. The number of immunoreactive cells expressing the A1R/ER combination was significantly increased in 12M rats, principally around follicles or cysts. M1R/PR staining was similarly increased in the 12M group, but the principal signal source was the stroma cells. The autonomic nervous system appears to participate in the loss of function of these structures with age in the rat ovary.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100225"},"PeriodicalIF":0.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143422470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monosodium glutamate (MSG) exposure induced oxidative stress and disrupted testicular hormonal regulation, exacerbating reproductive dysfunction in male WISTAR rats","authors":"Adesua Emmanuel Ogunmokunwa,&nbsp;Babatunde Oluwaseun Ibitoye","doi":"10.1016/j.endmts.2025.100226","DOIUrl":"10.1016/j.endmts.2025.100226","url":null,"abstract":"<div><h3>Background</h3><div>Monosodium glutamate (MSG) is a common food additive linked to various health concerns, including potential reproductive toxicity.</div></div><div><h3>Objective</h3><div>To investigate the effects of chronic, low-dose MSG on testicular hormones and oxidative stress biomarkers in adult male Wistar rats.</div></div><div><h3>Methods</h3><div>Thirty male Wistar rats were divided into five groups (<em>n</em> = 6 per group). The control group received distilled water, while the experimental groups were orally administered MSG at 30, 100, 300, and 1000 mg/kg body weight for 65 days. Hormonal levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone were measured using ELISA. Testicular oxidative stress markers, including malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), were assessed.</div></div><div><h3>Results</h3><div>MSG caused a dose-dependent decrease in LH, FSH, and testosterone levels, with the highest dose (1000 mg/kg) exhibiting the most significant reductions. MDA levels increased proportionally with MSG dosage, indicating heightened oxidative stress. Conversely, the activities of antioxidant enzymes (SOD, CAT, GSH, GPx) were significantly diminished, reflecting impaired antioxidant defences.</div></div><div><h3>Conclusion</h3><div>Chronic MSG exposure disrupts hormonal regulation and induces oxidative stress in a dose-dependent manner, potentially impairing male reproductive health. These findings underscore the need for further studies on the long-term reproductive effects of MSG and possible protective interventions.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100226"},"PeriodicalIF":0.0,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143377987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acromegaly: Is earlier diagnosis possible? Exploration of a screening algorithm to select high-risk patients","authors":"Tessa N.A. Slagboom ,&nbsp;David de Jong ,&nbsp;Peter H. Bisschop ,&nbsp;Madeleine L. Drent","doi":"10.1016/j.endmts.2025.100223","DOIUrl":"10.1016/j.endmts.2025.100223","url":null,"abstract":"<div><h3>Purpose</h3><div>Given the ongoing need to reduce the delay in diagnosis of acromegaly, the aim of the current study was to develop a screening algorithm that: finds as many patients as possible who have already been diagnosed with acromegaly (=sensitivity), while identifying a limited number of additional patients who are at risk for acromegaly as a proxy for specificity.</div></div><div><h3>Methods</h3><div>CTcue data mining software (version 4.7, IQVIA Inc., USA) was used to develop a screening algorithm. Data were extracted from the electronic health records of a tertiary centre. Multiple sources (literature review, real-world evidence and expert opinion) were used to identify predictors such as clinical manifestations, comorbidities and frequently consulted specialists, for inclusion in the algorithm. Based on different combinations of predictors, several exploratory search strategies were constructed in CTcue and algorithms with the highest sensitivity were further adapted.</div></div><div><h3>Results</h3><div>A total of 68 predictors were identified and grouped into 5 categories. After exploratory analysis and fine-tuning, an algorithm combining pathognomonic changes in clinical appearance with manifestations considered by medical experts to be most characteristic of acromegaly (hyperhidrosis, sleep apnoea, arthralgia, headache and type 2 diabetes mellitus) detected 48/90 of patients with previously diagnosed acromegaly, while identifying an additional 1844/1,7 million of possible at-risk patients.</div></div><div><h3>Conclusion</h3><div>We found that our best algorithm led to the detection of more than half of patients with previously diagnosed acromegaly. The same algorithm identified 0.1 % of the hospital population as potentially having acromegaly, which is approximately 10 times higher than the estimated worldwide prevalence. These results seem promising but need further improvement and validation.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100223"},"PeriodicalIF":0.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143372465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective clinical analysis of time to recovery from diabetic ketoacidosis in Ethiopia","authors":"Angefa Ayele ,&nbsp;Dube Jara ,&nbsp;Alo Edin ,&nbsp;Digafe Hailu ,&nbsp;Mihiret Kifle ,&nbsp;Yohannes Fekadu","doi":"10.1016/j.endmts.2025.100224","DOIUrl":"10.1016/j.endmts.2025.100224","url":null,"abstract":"<div><h3>Background</h3><div>Diabetes is a metabolic disorder that affected &gt; or = 500 million people in 2021. Diabetic ketoacidosis is the most serious acute complication. Because of the significant health burden of diabetic ketoacidosis, we performed a retrospective study on the recovery time and predictors among adult diabetic mellitus patients in selected public hospitals in Southern Oromia in Ethiopia.</div></div><div><h3>Methods</h3><div>A retrospective follow-up study was conducted of 316 randomly selected adult diabetic ketoacidosis patients admitted between January 1, 2020, and July 31, 2023. A structured checklist was utilized. Data were entered into Epi-data version 4.6 and analyzed with STATA version 17, employing Kaplan-Meier survival curves, log-rank tests, and Cox-proportional hazards models to identify predictors. Results from bivariable and multivariable Cox-regression were reported via adjusted hazard ratio with 95 % confidence intervals.</div></div><div><h3>Results</h3><div>This study included 316 participants, with 256 adults (81.01 %) recovering throughout the follow-up period. The overall DKA recovery rate was 23.8 per 1000 person-hours (95 % CI: 22.21–27.07), and the median recovery time was 42 hr. Significant predictors of recovery time included random blood glucose level [AHR (95 % CI): 0.58 (0.38–0.90)], duration of diabetes mellitus [AHR (95 % CI): 0.24 (0.14–0.69)], and severity of DKA [AHR (95 % CI): 0.46 (0.16–0.84)].</div></div><div><h3>Conclusion</h3><div>The median DKA recovery time was prolonged, increasing the risk of complications. Blood glucose level, diabetes duration, and DKA severity were predictors of recovery time. Therefore, targeting these factors through research and interventions may improve outcomes and reduce DKA recovery duration.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100224"},"PeriodicalIF":0.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geospatial analysis and determinant factors of comorbidity presence in patients with diabetes in Peru","authors":"Víctor Juan Vera-Ponce ,&nbsp;Fiorella E. Zuzunaga-Montoya ,&nbsp;Luisa Erika Milagros Vásquez-Romero ,&nbsp;Joan A. Loayza-Castro ,&nbsp;Nataly Mayely Sanchez-Tamay ,&nbsp;Carmen Inés Gutierrez De Carrillo","doi":"10.1016/j.endmts.2025.100222","DOIUrl":"10.1016/j.endmts.2025.100222","url":null,"abstract":"<div><h3>Objective</h3><div>Given the significant increase in diabetes mellitus (DM) prevalence and its associated complications in recent decades, this study aimed to explore the determinant factors and geographical distribution of comorbidities and their number in patients with diabetes in Peru.</div></div><div><h3>Methods</h3><div>Cross-sectional study based on a database providing detailed demographic and clinical information on DM patients affiliated with the Seguro Integral de Salud (SIS) in Peru. The dependent variables in this study are twofold: the type of comorbidities present in DM patients and the number of comorbidities they have. Comorbidities were categorized into three groups: DM with obesity/dyslipidemia, DM with hypertension, and DM with mental health disorders. The number of comorbidities was classified as none, one, two, or three comorbidities.</div></div><div><h3>Results</h3><div>A total of 1,355,354 patients were included. Male patients, older individuals, and those with a longer time since diagnosis have different probabilities of presenting the comorbidities and a higher number of them. Additionally, the geospatial analysis showed apparent regional variations in the prevalence and number of comorbidities, highlighting the influence of environmental and socioeconomic factors and access to healthcare services.</div></div><div><h3>Conclusions</h3><div>This study identified significant demographic and clinical factors associated with comorbidities in patients with DM in Peru. These findings showed the need for personalized, region-specific diabetes management. Therefore, public health policies should adapt to meet the needs of different regions and groups. Improving healthcare access is crucial, especially where comorbidity prevalence is high. Further education programs must address diet and exercise comorbidities, focusing on vulnerable people.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100222"},"PeriodicalIF":0.0,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between metabolic syndrome and gallstone disease: A cross-sectional study from the PERSIAN Guilan cohort study","authors":"Hasti Zakeri Fardi ,&nbsp;Kourosh Mojtahedi ,&nbsp;Saman Maroufizadeh ,&nbsp;Farahnaz Joukar ,&nbsp;Fariborz Mansour-Ghanaei","doi":"10.1016/j.endmts.2025.100221","DOIUrl":"10.1016/j.endmts.2025.100221","url":null,"abstract":"<div><h3>Background</h3><div>There has been a concerning increase in the occurrence of gallstone diseases (GSDs) among individuals with metabolic syndrome (MetS). This study investigated the association between MetS and GSDs and related risk factors.</div></div><div><h3>Methods</h3><div>This retrospective cross-sectional study was conducted on 10,520 participants from the prospective epidemiological research studies of the Iranian adults (PERSIAN) Guilan cohort study (PGCS) population. Demographic and clinical characteristics, anthropometric parameters, and laboratory findings were collected. National Cholesterol Education Program–Adult Treatment Panel III criteria (NCEP-ATP III) were used to diagnose the MetS. All data was analyzed using SPSS version 26, and a significant level was considered &lt;0.05.</div></div><div><h3>Results</h3><div>The prevalence of MetS was 41.8 %, with higher rates in females (56.3 %) than males (25.0 %). Also, GSD prevalence was 2.06 %. Abdominal obesity and low high-density lipoprotein (HDL) levels were significantly associated with GSDs (<em>P</em> &lt; 0.05). The presence of MetS increased GSD odds by 47 % (<em>P=</em>0.010). A trend of increasing GSD prevalence with the number of MetS components illustrated a significant relationship ranging from 0.56 % (no components) to 3.60 % (all components) (<em>P</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>The findings demonstrated that MetS was significantly associated with increased risk of GSDs, of which higher body mass index (BMI), greater waist circumference, and lower HDL level were the most associated risk factors.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100221"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}